- Home
- RNAC vs NGNE Comparison
RNAC vs NGNE Comparison
Compare RNAC & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNAC
- NGNE
- Stock Information
- Founded
- RNAC 2007
- NGNE 2003
- Country
- RNAC United States
- NGNE United States
- Employees
- RNAC N/A
- NGNE N/A
- Industry
- RNAC Biotechnology: Pharmaceutical Preparations
- NGNE Biotechnology: Pharmaceutical Preparations
- Sector
- RNAC Health Care
- NGNE Health Care
- Exchange
- RNAC Nasdaq
- NGNE Nasdaq
- Market Cap
- RNAC 276.3M
- NGNE 325.3M
- IPO Year
- RNAC 2016
- NGNE N/A
- Fundamental
- Price
- RNAC $10.05
- NGNE $18.48
- Analyst Decision
- RNAC Strong Buy
- NGNE Strong Buy
- Analyst Count
- RNAC 4
- NGNE 7
- Target Price
- RNAC $40.00
- NGNE $41.86
- AVG Volume (30 Days)
- RNAC 48.4K
- NGNE 110.1K
- Earning Date
- RNAC 08-07-2025
- NGNE 08-11-2025
- Dividend Yield
- RNAC N/A
- NGNE N/A
- EPS Growth
- RNAC N/A
- NGNE N/A
- EPS
- RNAC N/A
- NGNE N/A
- Revenue
- RNAC $1,026,000.00
- NGNE N/A
- Revenue This Year
- RNAC N/A
- NGNE N/A
- Revenue Next Year
- RNAC N/A
- NGNE N/A
- P/E Ratio
- RNAC N/A
- NGNE N/A
- Revenue Growth
- RNAC N/A
- NGNE N/A
- 52 Week Low
- RNAC $8.46
- NGNE $6.88
- 52 Week High
- RNAC $26.50
- NGNE $74.49
- Technical
- Relative Strength Index (RSI)
- RNAC 34.71
- NGNE 35.93
- Support Level
- RNAC $10.50
- NGNE $19.59
- Resistance Level
- RNAC $11.80
- NGNE $20.46
- Average True Range (ATR)
- RNAC 0.56
- NGNE 1.23
- MACD
- RNAC -0.11
- NGNE -0.20
- Stochastic Oscillator
- RNAC 0.45
- NGNE 13.37
About RNAC Cartesian Therapeutics Inc.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.